Compare Global X Cloud Computing ETF (CLOU) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Cloud Computing ETF vs Viatris Inc — how do they compare? Global X Cloud Computing ETF trades at $24.54, while Viatris Inc trades at $16.46 (market cap $18.99B). The key difference: Viatris Inc pays a 2.94% dividend while Global X Cloud Computing ETF pays none, and Viatris Inc is trading nearer its 52-week high, Global X Cloud Computing ETF nearer its low. Which is the better fit depends on your goals.
| CLOU | VTRS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $26.38 | $17.39 |
52-Week Low | $17.60 | $8.74 |
Market Cap | — | $18.99B |
Enterprise Value | — | $31.20B |
Dividend Yield | — | 2.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CLOU trades at $24.11, up 1.49% with a bullish technical signal from moving averages. The ETF shows strong institutional interest in cloud computing exposure but faces mixed oscillators with RSI indicating overbought conditions. Recent news highlights both opportunity in underperforming tech sectors and concerns about cloud ETF performance trends.
The outlook balances cloud computing's growth potential against valuation concerns and sector volatility. Investment opportunity lies in AI-driven cloud adoption, while risks include competitive pressures and the ETF's historical underperformance compared to broader tech indices.
Viatris (VTRS) trades at $16.39, up 0.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, with improving cash flow trends and a consensus price target of $20. Recent positive Phase 3 results for VR-205 and FDA acceptance of a new drug application highlight pipeline progress.
The outlook is mixed: strong analyst buy ratings and a 22% upside to target suggest value, but profitability challenges and high debt pose risks. Investors should weigh the potential from pipeline catalysts against ongoing margin pressure and competitive threats in the generic drug space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X Cloud Computing ETF
CLOU is a thematic ETF that invests in companies leading the cloud revolution. It targets providers of SaaS, PaaS, and IaaS, including major firms like Salesforce, Akamai, and Shopify that drive modern digital infrastructure.
Read more on CLOU →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
